Forty Seven * website screenshot

Forty Seven *

Forty Seven, Inc. was an immuno-oncology biotechnology company founded in 2015 to commercialize CD47 immune-evasion research licensed from Stanford University (Irv Weissman and colleagues). Its lead program was magrolimab, a monoclonal antibody targeting CD47 — the "do not eat me" signal tumor cells use to evade macrophage-mediated killing — studied in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and diffuse large B-cell lymphoma (DLBCL). Backed by GV, the company was acquired by Gilead Sciences in 2020 for roughly $4.9 billion; the fortyseveninc.com domain now redirects to gilead.com. As a clinical-stage therapeutics company it exposes no public developer API surface.

Forty Seven * is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Immuno-Oncology, and Oncology.

🌐 Visit website 📡 Source on GitHub
7.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyLife SciencesBiotechnologyImmuno-OncologyOncologyPharmaceuticalsCancerTherapeutics

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 7.7/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.0 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/forty-seven: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Forty Seven Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Company 1

The organization behind the API

Website
Website

Source (apis.yml)

apis.yml Raw ↑ 
aid: forty-seven
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/forty-seven.png
name: Forty Seven *
description: Forty Seven, Inc. was an immuno-oncology biotechnology company founded in 2015 to commercialize CD47 immune-evasion
  research licensed from Stanford University (Irv Weissman and colleagues). Its lead program was magrolimab, a monoclonal
  antibody targeting CD47 — the "do not eat me" signal tumor cells use to evade macrophage-mediated killing — studied in myelodysplastic
  syndrome (MDS), acute myeloid leukemia (AML), and diffuse large B-cell lymphoma (DLBCL). Backed by GV, the company was acquired
  by Gilead Sciences in 2020 for roughly $4.9 billion; the fortyseveninc.com domain now redirects to gilead.com. As a clinical-stage
  therapeutics company it exposes no public developer API surface.
url: https://raw.githubusercontent.com/api-evangelist/forty-seven/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Life Sciences
- Biotechnology
- Immuno-Oncology
- Oncology
- Pharmaceuticals
- Cancer
- Therapeutics
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/forty-seven-domain-security.yml
- type: Website
  url: http://fortyseveninc.com
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence